<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nervgen Pharma Corp. — News on 6ix</title>
    <link>https://6ix.com/company/nervgen-pharma-corp-1</link>
    <description>Latest news and press releases for Nervgen Pharma Corp. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nervgen-pharma-corp-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7708c51cc36e47533dc1f.webp</url>
      <title>Nervgen Pharma Corp.</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1</link>
    </image>
    <item>
      <title>NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as-chief-financial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as-chief-financial-officer</guid>
      <pubDate>Mon, 27 Apr 2026 11:30:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company’s financial strategy and operations, incl</description>
    </item>
    <item>
      <title>NervGen Pharma to Participate in the H.C. Wainwright &quot;HCW@Home&quot; Series and the 2026 Bloom Burton &amp; Co. Healthcare Investor Conference</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-participate-in-the-hc-wainwright-hcwhome-series-and-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-participate-in-the-hc-wainwright-hcwhome-series-and-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
      <pubDate>Mon, 13 Apr 2026 11:45:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate in the H.C.</description>
    </item>
    <item>
      <title>NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic-tetraplegia</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic-tetraplegia</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint</description>
    </item>
    <item>
      <title>NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-reports-full-year-2025-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-reports-full-year-2025-financial-results-and-provides-business-updates</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3</description>
    </item>
    <item>
      <title>NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-voluntary-delisting-from-tsx-venture-exchange-55</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-voluntary-delisting-from-tsx-venture-exchange-55</guid>
      <pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
      <description>The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN”No action is required; all shareholders, including Canadian shareholders,</description>
    </item>
    <item>
      <title>NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-appoints-shamim-ruff-as-chief-regulatory-affairs-officer-and-christine-mcsherry-as-svp-patient-advocacy-and-clinical-affairs-7</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-appoints-shamim-ruff-as-chief-regulatory-affairs-officer-and-christine-mcsherry-as-svp-patient-advocacy-and-clinical-affairs-7</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a</description>
    </item>
    <item>
      <title>NervGen Pharma to Participate at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-participate-at-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-participate-at-upcoming-investor-conferences</guid>
      <pubDate>Wed, 18 Feb 2026 12:30:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate</description>
    </item>
    <item>
      <title>NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams</guid>
      <pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage</description>
    </item>
    <item>
      <title>NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-present-at-unite2fight-paralysis-20th-annual-science-and-advocacy-symposium</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-present-at-unite2fight-paralysis-20th-annual-science-and-advocacy-symposium</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
      <description>Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spi</description>
    </item>
    <item>
      <title>NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-appoints-adam-rogers-as-chief-executive-officer-to-continue-leading-the-companys-growth-and-execution-of-its-mission-in-spinal-cord-injury</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-appoints-adam-rogers-as-chief-executive-officer-to-continue-leading-the-companys-growth-and-execution-of-its-mission-in-spinal-cord-injury</guid>
      <pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage</description>
    </item>
    <item>
      <title>NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing</title>
      <link>https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-ring-the-nasdaq-closing-bell-on-january-22-2026-celebrating-its-recent-nasdaq-listing</link>
      <guid isPermaLink="true">https://6ix.com/company/nervgen-pharma-corp-1/news/nervgen-pharma-to-ring-the-nasdaq-closing-bell-on-january-22-2026-celebrating-its-recent-nasdaq-listing</guid>
      <pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company&quot;) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City. Adam Rogers, MD, Chairman and Inter</description>
    </item>
  </channel>
</rss>